PubMed COVID-19 Clinical Care

We present a general analytical method for obtaining unbiased prevalence estimates based on data from regional or national testing programs, where individual participation in the testing program is voluntary but where additional questionnaire data is

CONCLUSIONS: There is little evidence to suggest there have been any major increases in epilepsy-related deaths in Scotland during the COVID-19 pandemic. COVID-19 is a common underlying cause of both epilepsy-related and unrelated deaths.

CONCLUSIONS: COVID-19 is an asymptomatic-mild disease in most young healthy children, with gradually diminishing emotional symptoms. Children without prolonged respiratory symptoms revealed no significant pulmonary sequelae as evaluated by EBC

No abstract

Utilising a retrospective cohort study of SARS-CoV-2 wildtype (Wuhan) strain, we aimed to 1) utilise the unique Australian experience of temporarily eliminating SARS-CoV-2 to document and estimate the hospitalisation demand; and 2) estimate the

Most studies on the long-term effects of SARS-CoV-2 infection have been retrospective, have lacked an uninfected comparison group, and have focussed on the prevalence of individual symptoms, resulting in different estimates of prevalence. Recognizing

In the period of the corona virus disease 2019 (COVID-19) outbreak, an alcohol-based hand sanitizer is one of the most in-demand products for disinfection purposes. Two major concerns are adulteration of methanol, which causes toxicity to human

To effectively mitigate the spread of communicable diseases, it is necessary to understand the interactions that enable disease transmission among individuals in a population; we refer to the set of these interactions as a contact network. The

CONCLUSION: The combined fluvoxamine treatment did not add benefit in preventing deterioration in mild-to-moderate COVID-19 patients without the immunomodulatory effect observed, although it demonstrated low hospitalization rates, oxygen supplemental

CONCLUSION: Given the ongoing strain and demand of COVID-19 on the healthcare system, a centralized, multi-disciplinary team of experts allowed for efficient delivery of COVID-19 therapies through one provider touchpoint. The collaboration between